Research Project
Grant-in-Aid for Young Scientists (B)
Erlotinib, EGFR tyrosine kinase inhibitor, is an effective therapeutic agent for non-small cell lung cancer. However, inherent or acquired chemoresistance is known to be a major obstacle for anti-cancer therapies. I have isolated erlotinib resistant human non-small cell lung cancer A549 cells. PAK-104P inhibits the functions of p-gp, MRP1, MRP2 and Major vault protein (MVP). PAK-104P partially reversed the erlotinib resistance. It has been reported that the MVP mediates resistance to epidermal growth factor receptor-targeting agent such as erlotinib. I identified the crucial MVP promoter elements that regulate MVP expression. By deletion analysis, a conserved proximal E-box binding site was demonstrated to be important for human MVP promoter transactivation. Introduction of siRNA against USF 1 , which is known to bind the E-box binding site, decreased the expression of MVP. These findings suggest that USF1 binding to an E-box element may be critical for basal MVP promoter activation.
All 2014 2013 2012 2011 Other
All Journal Article (29 results) (of which Peer Reviewed: 29 results) Presentation (30 results) Book (1 results)
Oncol. Rep
Volume: 31 Pages: 719-726
Rep.
Volume: 31 Pages: 197-201
Oncology Reports
J. Dermatol
Volume: 40 Pages: 1020-1026
Oncotarget
Volume: 4 Pages: 2261-2270
Int. J. Mol. Med
Volume: 32 Pages: 703-708
Volume: 30 Pages: 1444-1448
J. Oncol
Volume: 43 Pages: 746-754
J. Endocrinol
Volume: 217 Pages: 141-150
International Journal of Molecular Medicine
International Journal of Oncology
Journal of Endocrinology
Journal of Dermatological Science
Volume: 68 Pages: 19-24
Am. J. Health Syst. Pharm
Volume: 69 Pages: 1509-1512
J. Dermatol. Sci
Oncol. Lett
Volume: 3 Pages: 995-1001
Peptides
Volume: 36 Pages: 299-302
Rep
Volume: 28 Pages: 27-32
Volume: 28 Pages: 895-902
Oncolgy Letters
Volume: 2 Pages: 299-302
American Journal of Health-System Pharmacy
Oncol. Rep.
Volume: In press
Biol. Pharm. Bull
Volume: 34 Pages: 1418-1425
130001872434
Volume: 34 Pages: 433-435
130000657826
Biol. Pharm. Bull.